Alpha Tau Medical Ltd.
DRTS evidence brief
What we can confirm
- BioSniper Score:
- 4.5 / 10
- Market Cap:
- $1.43B
What it means
What to watch
Prepared research question
What matters most for DRTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DRTS
Alpha Tau Medical Ltd. (DRTS) is a clinical-stage oncology company developing Alpha DaRT®, a proprietary alpha-radiation cancer therapy, with ongoing trials in skin, pancreatic, and brain cancers and key data readouts expected in 2026.
Key risk: Pre-revenue stage
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.43B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 21 clinical trials for Alpha Tau Medical Ltd..
Alpha Tau Medical Ltd. (DRTS) is a clinical-stage oncology company developing Alpha DaRT®, a proprietary alpha-radiation cancer therapy, with ongoing trials in skin, pancreatic, and brain cancers and key data readouts expected in 2026.
- Developer of Alpha DaRT®, an innovative alpha-radiation cancer therapy [news · published 2025-12-18].
- Cash & equivalents of $12.2M and shareholders' equity of $77.1M as of 2025-12-31 [sec].
- Five concurrent U.S. trials including the ReSTART pivotal skin cancer trial and internal organ cancer trials in pancreas and brain [news · published 2026-01-29].
- Expected Phase 2 topline data readout for Alpha DaRT in pancreatic cancer by 2026-12-31 [catalyst].
- Presented corporate overview at the J.P. Morgan 2026 Healthcare Conference in January 2026 [news · published 2025-12-18].
What works
- Multiple near-term catalysts: Phase 2 pancreatic readout and GBM interim results are expected in 2026, providing potential value-driving milestones [catalyst][news · published 2026-05-08].
- Ramping U.S. manufacturing for commercial readiness, indicating preparation for potential market entry [news · published 2026-01-29].
- Five concurrent U.S. trials demonstrate a broad clinical pipeline across different cancer types [news · published 2026-01-29].
What to weigh
- As a clinical-stage company, Alpha Tau has no approved products yet and is dependent on successful trial outcomes for future revenue [news · published 2026-01-29].
- Cash position of $12.2M as of 2025-12-31 may limit runway if trials require additional funding before commercialization [sec].
- Competitive landscape includes multiple large players (e.g., Merck, VelaVigo Bio) developing novel oncology therapies, increasing market risk [competitor_trial].
From the filings
Quoted directly from source documents.
Alpha Tau is developing Alpha DaRT alpha-radiation therapy
“the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®”
News · January 29, 2026
Phase 2 pancreatic readout expected by end of 2026
“Phase 2 topline data readout for alpha dart in pancreatic”
Catalysts · December 31, 2026
Five concurrent U.S. trials including ReSTART pivotal skin cancer trial
“Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead”
News · January 29, 2026
Catalyst timeline
- 2026-12-31 · Phase 2 Readout: alpha dart - Expected Phase 2 topline data readout for alpha dart in pancreatic — This is the expected topline data readout for the pancreatic cancer trial, a key value-driving milestone.
Risks & what to watch (3)›
Key risks
- Pre-revenue stage — No approved products; all revenue dependent on future clinical success [news · published 2026-01-29]
- Cash runway constraints — $12.2M cash as of 2025-12-31 may be insufficient for extended operations without financing [sec]
- Competitive oncology landscape — Multiple competitors (Merck, VelaVigo Bio) with advanced therapies in similar indications [competitor_trial]
What to watch
- Phase 2 topline data readout for Alpha DaRT in pancreatic cancer by 2026-12-31 [catalyst]
- Interim results from the first three patients treated for recurrent glioblastoma, discussed in a conference call on 2026-05-08 [news · published 2026-05-08]
- Patient accrual completions and subsequent data readouts from the ReSTART pivotal skin cancer trial [news · published 2026-01-29]
- Commercial manufacturing ramp-up in the U.S. [news · published 2026-01-29]
Sources: Catalysts · Competitor trials · News · Generated October 10, 2026 · How we verify sources →
Run Alpha Tau Medical Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alpha Tau Medical Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.37
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 12 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
53
Total value held
$29.0M
| Holder | Shares | Value |
|---|---|---|
| hightower advisors, llc | 874,994 | $6.2M |
| aquamarine financial (cayman) ltd | 721,501 | $5.1M |
| apella capital, llc | 382,284 | $3.1M |
| ark investment management llc | 292,134 | $2.1M |
| ubs group ag | 286,688 | $2.0M |
| northcoast asset management llc | 147,138 | $1.0M |
| daytona street capital llc | 146,106 | $1.0M |
| mariner, llc | 146,396 | $1.0M |
| gem investment advisors, llc | 113,736 | $804K |
| levin capital strategies, l.p. | 106,423 | $752K |
Showing top 10 of 53 institutional holders of Alpha Tau Medical Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 3.4
- Shares short
- 1,018,069
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DRTS short interestFrequently asked questions
What is the AI investment thesis for Alpha Tau Medical Ltd.?
Alpha Tau Medical Ltd. (DRTS) is a clinical-stage oncology company developing Alpha DaRT®, a proprietary alpha-radiation cancer therapy, with ongoing trials in skin, pancreatic, and brain cancers and key data readouts expected in 2026.
Who is the CEO of Alpha Tau Medical Ltd.?
Mr. Uzi Sofer is the chief executive officer of Alpha Tau Medical Ltd. (DRTS).
Where is Alpha Tau Medical Ltd. headquartered?
Alpha Tau Medical Ltd. (DRTS) is headquartered in Jerusalem, Israel.
What therapeutic areas does Alpha Tau Medical Ltd. focus on?
Alpha Tau Medical Ltd. develops therapies across Oncology, Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.